Kaitlyn D’Onofrio

DocwireNews

A retrospective study found that ocrelizumab was safe, effective, and well tolerated in patients with primary progressive multiple sclerosis (PPMS) and relapsing multiple sclerosis (RMS) in a clinical practice setting.Clinical and MRI data for patients with PPMS and RMS at two health areas in southeastern Spain were collected. All patients received at least one infusion of ocrelizumab. Patients who were enrolled in an ocrelizumab trial or who had less than six months of follow-up were excluded.Seventy patients were assessed, of whom 42 were women; 30% had PPMS, and 70% had RMS. Patients with PPMS were older than those with RMS (mean age at baseline, 47.1 years vs. 39.2 years). The median Expanded Disability Status Scale&nbsp;was 3.0 in the PPMS group and 2.5 in the RMS group. Median follow-up for the cohort was 13.6 months, during which time patients underwent a median three treatment cycles.After starting ocrelizumab, the majority of patients did not experience clinical or MRI activity. More than half of patients had T1 Gd-enhancing lesions at baseline (57%), and at the first MRI control after four to six months, 69 of 70 of these patients no longer had T1 Gd-enhancing lesions (98.6%; P&lt;0.001). Among patients with RMS and at least one year of follow-up, 94% achieved no evidence of disease activity. The most frequent adverse events were infusion-related reactions and infections, but none were serious.

Jordana Jampel

Brensocatib Shows Positive Results for Managing Bronchiectasis Symptoms

Pulmonology

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Latest News

Safety, Efficacy of Ocrelizumab for MS in Clinical Practice Setting

Multiple Sclerosis

A retrospective study found that ocrelizumab was safe, effective, and well tolerated in patients with primary progressive multiple sclerosis (PPMS) and relapsing multiple ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe